A smarter aging clock targets older adults
Most biological aging clocks are trained on chronological age, but that introduces a hidden flaw: people who are still alive at seventy or eighty are already the survivors. A new clock built on the Framingham Heart Study tries to correct for that bias.
When aging clocks learn from older study participants, they inevitably pick up signals of survival resilience as much as biological aging itself. This can make it hard to detect whether a given intervention is actually slowing deterioration, or whether the clock is simply insensitive to the change.
An alternative approach trains a clock not on age in years, but on the rate at which organ functions decline over time. This is called a Pace of Aging measure. An earlier version, DunedinPACE, demonstrated sensitivity to calorie restriction, the best-established intervention for slowing aging in laboratory models. But DunedinPACE was built using data from healthy, relatively young adults in the Dunedin Longitudinal Study.
The researchers applied the same methodology to the Framingham Heart Study Offspring Cohort, an older and more clinically diverse population. The goal was to determine whether DunedinPACE’s sensitivity to calorie restriction reflected the design of the clock itself, or simply the demographic similarity between the populations used for development and for testing.
Why this matters for trials
Clinical trials testing longevity interventions need a reliable measuring stick. If the clock does not respond to real biological changes in the study population, a negative result could reflect a poor measurement tool rather than an ineffective treatment. Building clocks in populations that resemble future trial participants is therefore a practical priority.
What remains unknown
Whether the new Framingham-based clock is sensitive to interventions other than calorie restriction has not yet been tested. How it compares to existing clocks in actual clinical trials is also still to be determined. This is careful, methodological science: less visible than a new drug, but essential groundwork for evaluating whether any longevity treatment is working at all.
Want to research this yourself?
Search for example:
- pace of aging biomarker clinical trial sensitivity
- organ function decline longitudinal measurement
- survivorship bias aging cohort